These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30845347)

  • 1. Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours.
    Faessel H; Nemunaitis J; Bauer TM; Lockhart AC; Faller DV; Sedarati F; Zhou X; Venkatakrishnan K; Harvey RD
    Br J Clin Pharmacol; 2019 Jul; 85(7):1464-1473. PubMed ID: 30845347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study assessing the mass balance, pharmacokinetics, and excretion of [
    Zhou X; Sedarati F; Faller DV; Zhao D; Faessel HM; Chowdhury S; Bolleddula J; Li Y; Venkatakrishnan K; Papai Z
    Invest New Drugs; 2021 Apr; 39(2):488-498. PubMed ID: 33089874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.
    Lockhart AC; Bauer TM; Aggarwal C; Lee CB; Harvey RD; Cohen RB; Sedarati F; Nip TK; Faessel H; Dash AB; Dezube BJ; Faller DV; Dowlati A
    Invest New Drugs; 2019 Feb; 37(1):87-97. PubMed ID: 29781056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies.
    Faessel HM; Mould DR; Zhou X; Faller DV; Sedarati F; Venkatakrishnan K
    Br J Clin Pharmacol; 2019 Nov; 85(11):2568-2579. PubMed ID: 31355467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib.
    Malhi V; Colburn D; Williams SJ; Hop CE; Dresser MJ; Chandra P; Graham RA
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):41-9. PubMed ID: 27154174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.
    Fukumura K; Kawaguchi N; Ishibashi T; Kubota R; Tada Y; Ogura E
    Clin Drug Investig; 2020 Jun; 40(6):529-540. PubMed ID: 32323104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
    Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S
    J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: An open-label, phase I study in healthy subjects.
    Tachibana M; Matsuki S; Maekawa Y; Kuroda K; Shimizu T; Tsutsumi J; Ishizuka H
    Clin Transl Sci; 2023 Nov; 16(11):2153-2162. PubMed ID: 37705321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs.
    Nomoto M; Zamora CA; Schuck E; Boyd P; Chang MK; Aluri J; Siu YA; Lai WG; Yasuda S; Ferry J; Rege B
    Br J Clin Pharmacol; 2018 May; 84(5):952-960. PubMed ID: 29341245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors.
    Zhou X; Vaishampayan U; Mahalingam D; Harvey RD; Chung KY; Sedarati F; Dong C; Faller DV; Venkatakrishnan K; Gupta N
    Invest New Drugs; 2022 Oct; 40(5):1042-1050. PubMed ID: 35932388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.
    Swords RT; Erba HP; DeAngelo DJ; Bixby DL; Altman JK; Maris M; Hua Z; Blakemore SJ; Faessel H; Sedarati F; Dezube BJ; Giles FJ; Medeiros BC
    Br J Haematol; 2015 May; 169(4):534-43. PubMed ID: 25733005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
    Tugnait M; Gupta N; Hanley MJ; Sonnichsen D; Kerstein D; Dorer DJ; Venkatakrishnan K; Narasimhan N
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):214-223. PubMed ID: 31287236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials.
    Dymond AW; So K; Martin P; Huang Y; Severin P; Mathews D; Lisbon E; Mariani G
    Eur J Clin Pharmacol; 2017 Feb; 73(2):175-184. PubMed ID: 27889832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.
    Bhatia S; Pavlick AC; Boasberg P; Thompson JA; Mulligan G; Pickard MD; Faessel H; Dezube BJ; Hamid O
    Invest New Drugs; 2016 Aug; 34(4):439-49. PubMed ID: 27056178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study.
    Mu S; Lin C; Skrzypczyk-Ostaszewicz A; Bulat I; Maglakelidze M; Skarbova V; Andreu-Vieyra C; Sahasranaman S
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):81-88. PubMed ID: 33772633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study.
    Poggesi I; Li LY; Jiao J; Hellemans P; Rasschaert F; de Zwart L; Snoeys J; De Meulder M; Mamidi RNVS; Ouellet D
    Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):101-111. PubMed ID: 31673875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perpetrator effects of ciclosporin (P-glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers.
    Brings A; Lehmann ML; Foerster KI; Burhenne J; Weiss J; Haefeli WE; Czock D
    Br J Clin Pharmacol; 2019 Jul; 85(7):1528-1537. PubMed ID: 30912163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Strong Inhibition of Cytochrome P450 3A and UDP glucuronosyltransferase 1A9 and Strong Induction of Cytochrome P450 3A on the Pharmacokinetics, Safety, and Tolerability of Soticlestat: Two Drug-Drug Interaction Studies in Healthy Volunteers.
    Yin W; Dong C; Stevenson A; Lloyd V; Petrillo M; Baratta M; Hui T; Han S
    Drug Metab Dispos; 2024 Feb; 52(3):180-187. PubMed ID: 38123352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Itraconazole, a Potent CYP3A4 Inhibitor, on the Steady-State Pharmacokinetics of Vemurafenib in Patients With BRAF
    Zhang W; Mathisen M; Goodman GR; Forbes H; Song Y; Bertran E; Demidov L; Shin SJ
    Clin Pharmacol Drug Dev; 2021 Jan; 10(1):39-45. PubMed ID: 32602215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.
    Vishwanathan K; Dickinson PA; So K; Thomas K; Chen YM; De Castro Carpeño J; Dingemans AC; Kim HR; Kim JH; Krebs MG; Chih-Hsin Yang J; Bui K; Weilert D; Harvey RD
    Br J Clin Pharmacol; 2018 Jun; 84(6):1156-1169. PubMed ID: 29381826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.